Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.91 AUD | +0.20% | +9.55% | +47.92% |
Sales 2024 * | 734M 480M 655M | Sales 2025 * | 911M 595M 812M | Capitalization | 4.93B 3.22B 4.4B |
---|---|---|---|---|---|
Net income 2024 * | 46M 30.05M 41.04M | Net income 2025 * | 88M 57.48M 78.51M | EV / Sales 2024 * | 6.53 x |
Net cash position 2024 * | 129M 84.5M 115M | Net cash position 2025 * | 197M 128M 175M | EV / Sales 2025 * | 5.19 x |
P/E ratio 2024 * |
104
x | P/E ratio 2025 * |
55.2
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.41% |
Latest transcript on Telix Pharmaceuticals Limited
1 day | +0.20% | ||
1 week | +9.55% | ||
Current month | +15.67% | ||
1 month | +16.21% | ||
3 months | +31.95% | ||
6 months | +72.37% | ||
Current year | +47.92% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Kluge
FOU | Founder | - | 15-10-31 |
Founder | - | 15-10-31 | |
Darren Smith
DFI | Director of Finance/CFO | 58 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harry McCann
CHM | Chairman | 83 | 17-09-16 |
Founder | - | 15-10-31 | |
Mark Nelson
BRD | Director/Board Member | - | 17-09-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.39% | 16 M€ | -8.49% | ||
0.04% | 773 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 14.91 | +0.20% | 1,700,410 |
24-04-24 | 14.88 | +4.06% | 1,735,593 |
24-04-23 | 14.3 | +1.42% | 1,508,493 |
24-04-22 | 14.1 | +3.60% | 1,052,608 |
24-04-19 | 13.61 | -0.80% | 1,407,698 |
Delayed Quote Australian S.E., April 26, 2024 at 02:10 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.92% | 3.21B | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TLX Stock